Welcome to our dedicated page for Tscan Therapeutics news (Ticker: TCRX), a resource for investors and traders seeking the latest updates and insights on Tscan Therapeutics stock.
TScan Therapeutics, Inc. (Nasdaq: TCRX) is a clinical-stage biotechnology company developing T cell receptor-engineered T cell (TCR-T) therapies for patients with cancer, with additional target discovery work in autoimmune disorders. The TCRX news page on Stock Titan aggregates company announcements, clinical updates, and regulatory disclosures so readers can follow how TScan’s programs evolve over time.
News coverage for TCRX often centers on the company’s hematologic malignancies program, particularly TSC-101 and the ALLOHA™ Phase 1 heme trial in patients with AML, ALL, or MDS undergoing allogeneic hematopoietic cell transplantation. Updates include clinical data readouts, such as relapse-free survival and overall survival observations, safety findings, and details on manufacturing process changes for TSC-101. Regulatory milestones, including alignment with the U.S. Food and Drug Administration on a pivotal trial design that mirrors the ALLOHA study, are also key topics in TScan’s press releases.
Investors and observers can also expect TCRX news about the PLEXI-T™ Phase 1 solid tumor trial, the company’s ImmunoBank of therapeutic TCRs, and its strategic decisions to prioritize the heme program while pausing further enrollment in the solid tumor trial. Additional updates highlight the development of in vivo-engineered TCR-T approaches for solid tumors, presentations at scientific meetings such as ASH, ASGCT, and ACR, and TargetScan-based discoveries in T cell-mediated autoimmune disorders.
Financial results, corporate strategy updates, workforce changes, and participation in investor conferences are reported through earnings releases and Form 8-K filings. By reviewing the TCRX news feed, readers gain context on TScan’s clinical progress, regulatory interactions, operational priorities, and research activities across oncology and autoimmunity.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
TScan Therapeutics, Inc. (TCRX) announced the appointment of Dr. Barbara Klencke to its Board of Directors, effective April 6, 2023. With over 20 years of oncology drug development experience, Dr. Klencke's expertise will enhance the company's clinical and commercial strategies as it advances its T cell receptor-engineered therapies for cancer. Key leadership promotions were also unveiled, with Shrikanta Chattopadhyay, Ann Hargraves, and Ray Lockard stepping up to Senior Vice President roles in Medical, Human Resources, and Technical Operations, respectively. These changes aim to strengthen TScan's operational capabilities and support ongoing clinical trials targeting hematologic malignancies and solid tumors throughout 2023.
TScan Therapeutics, Inc. (Nasdaq: TCRX) announced the appointment of Gavin MacBeath, Ph.D., as acting CEO, effective March 28, 2023, following the resignation of David Southwell. MacBeath, who has been with TScan since 2018 and has extensive experience in academia and industry, will continue to lead the company's clinical programs, including the recently dosed patient for TSC-101. TScan reports progress in clinical trials for hematologic malignancies and solid tumors, with plans for patient enrollment in the second quarter of 2023. As of December 31, 2022, the company had $120 million in cash, sufficient to fund operations into Q2 2024.
TScan Therapeutics has announced the successful dosing of the first patient in its Phase 1 clinical trial for TSC-101, aimed at treating leukemia and preventing relapse post-hematopoietic cell transplantation. This innovative therapy targets minor histocompatibility antigen HA-2 and is designed for patients with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), or acute lymphocytic leukemia (ALL). The trial, which includes TSC-100 and TSC-101, strives to improve outcomes for patients undergoing reduced intensity conditioning (RIC) prior to transplantation, addressing a significant relapse rate of approximately 40% in this population.
TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company specializing in T cell receptor (TCR)-engineered therapies, has announced participation in the Barclays Global Healthcare Conference on March 15, 2023, at 4:05 p.m. Eastern Time. This event will take place at the Loews Miami Beach Hotel. A webcast will be accessible on their website’s 'Events and Presentations' section, with an archived replay available for 90 days post-event.
The company focuses on TCR-T therapies for cancer treatment, with lead candidates TSC-100 and TSC-101 targeting hematologic malignancies and additional therapies for solid tumors.